Impact of Early-Onset or Worsening Anemia in Patients With Myelofibrosis Treated With Ruxolitinib: A Post Hoc Analysis of the JUMP Study.

Highlights from MPN Asia 2025: Advances in Molecular Pathogenesis and Therapeutic Strategies in Myeloproliferative Neoplasms.

A pharmacovigilance study of adverse events associated with polycythemia vera treatments using the FDA Adverse Event Reporting System (FAERS) database.

Time Without Transfusion Reliance (TWiTR): Integrating Survival Quality Into Myelofibrosis Treatment Strategies Based on the Phase 3 SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM Trials.

Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next-generation precision oncology to patients.

Population Impact of Using the PREVENT Equations to Guide the Management of Stage 1 Hypertension in the United States.

Earlier versus delayed ruxolitinib treatment for patients with myelofibrosis: a plain language summary.

Distress and Care Utilization in Patients with Myeloproliferative Neoplasms.

Length of Time in the United States and Cardiometabolic Outcomes Among Foreign and US-Born Black Adults.

Polycythemia vera: past, present and future.